Vaxcyte, Inc. $PCVX Shares Acquired by Polar Capital Holdings Plc

Polar Capital Holdings Plc raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 302.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,672,783 shares of the company’s stock after purchasing an additional 1,257,253 shares during the quarter. Polar Capital Holdings Plc’s holdings in Vaxcyte were worth $77,182,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Alberta Investment Management Corp acquired a new stake in shares of Vaxcyte during the 4th quarter valued at $1,389,000. Spruce Street Capital LP acquired a new position in shares of Vaxcyte in the 4th quarter worth $18,473,000. Vanguard Personalized Indexing Management LLC raised its position in shares of Vaxcyte by 59.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 25,224 shares of the company’s stock worth $1,164,000 after purchasing an additional 9,369 shares during the period. Mariner LLC lifted its holdings in shares of Vaxcyte by 10.1% during the fourth quarter. Mariner LLC now owns 8,539 shares of the company’s stock valued at $394,000 after purchasing an additional 784 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new position in shares of Vaxcyte in the 4th quarter valued at $4,406,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling

In related news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the transaction, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. The trade was a 9.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,500 shares of company stock valued at $419,288 over the last three months. 3.30% of the stock is owned by insiders.

Vaxcyte Trading Down 0.5%

Shares of PCVX stock opened at $49.31 on Wednesday. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of -7.17 and a beta of 1.24. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00. The stock’s fifty day simple moving average is $53.93 and its 200-day simple moving average is $52.68.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the firm earned ($1.04) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -7.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PCVX. BTIG Research lifted their price target on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.